EUCTR2006-006312-30-HU进行中（未招募）不适用
A phase IV non-randomized, uncontrolled, open-label, single-center trial to evaluate the safety and efficacy of Macugen (pegaptanib sodium) given by intravitreal injections every 6 weeks in patients with serous pigment epithel detachments (PED) in exudative age-related macular degeneration (AMD)
Dept. of Ophthalmol, Semmelweis University0 个研究点目标入组 30 人开始时间: 2007年1月25日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients of either gender
- •Age: 50 years or above
- •diagnosed with early lesions of serous pigment epithel detachments secondary to AMD
- •Early lesion defined as:
- •best corrected visual acuity >= 20/100,
- •detachments measuring < 6 disc areas
- •absence of any scarring/fibrosis or atrophy within the lesion
- •the absence of subfoveal hemorrhage or total hemorrhage representing greater than 1 disc area
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with prior treatment with PDT, or subfoveal laser and with clinically significant concomitant diseases will be excluded.
研究者
相似试验
进行中（未招募）
1 期
A phase IV, open, non-randomised, low-intervention clinical trial to evaluate the subjective user experience of Zeqmelit™ 6 mg mouth dissolving film for treatment of acute allergic reactioAcute allergic reactionMedDRA version: 20.1Level: LLTClassification code: 10000656Term: Acute allergic reaction Class: 10021428CTIS2023-504975-25-00AcuCort AB50
进行中（未招募）
1 期
Study of efficacy and safety of ranibizumab in patients with wet age related macular degeneration that have previously been treated with aflibercept.EUCTR2014-001085-10-DEovartis Pharmaceuticals UK Ltd124
进行中（未招募）
不适用
A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infected subjects with raised cholesterol - Rocket IIHIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2008-002043-16-ITGilead Sciences Europe Ltd160
进行中（未招募）
不适用
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol - ROCKET - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation TrialEUCTR2007-003354-28-GBGilead Sciences Limited
进行中（未招募）
不适用
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol - ROCKET II- Randomized Open Label Switch for Cholesterol Elevation on Kivexa+Kaletra Evaluation TrialAdult HIV-1 infected subjects on a stable HAART regimen of Kivexa + Kaletra, with raised cholesterolMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2008-002043-16-DEGilead Sciences Europe Ltd.160